Helmy M. Siragy
- Phone: 434-924-5629
- Fax: 434-924-1284
- Website: http://www.medicine.virginia.edu/clinical/departments/medicine/divisions/endocrine/research/labs/siragy
Primary Appointment
Professor, Medicine- Endocrinology and Metabolism
Education
- Fellowship, Endocrinology & Hypertension, The University of Texas Health Science Center at San Antonio
- Fellowship, Endocrinology & Hypertension, University of Virginia
- MD, Tanta University
- Residency, Internal Medicine, University of Texas, Galveston
Research Disciplines
Cardiovascular Biology, Physiology, Translational Science
Research Interests
Endocrine hypertension, angiotensin receptors, renal paracrine hormones
Research Description
Personal Statement
Selected Publications
Quadri S, Siragy HM, Regulation of (pro)renin receptor expression in mIMCD via the GSK-3β-NFAT5-SIRT-1 signaling pathway., 2014; American journal of physiology. Renal physiology. 307(5) F593-600. PMID: 24990896
Huang J, Ledford KJ, Pitkin WB, Russo L, Najjar SM, Siragy HM, Targeted deletion of murine CEACAM 1 activates PI3K-Akt signaling and contributes to the expression of (Pro)renin receptor via CREB family and NF-κB transcription factors., 2013; Hypertension. 62(2) 317-23. PMID: 23734002 | PMCID: PMC3793251
Matavelli LC, Huang J, Siragy HM, In vivo regulation of renal expression of (pro)renin receptor by a low-sodium diet., 2012; American journal of physiology. Renal physiology. 303(12) F1652-7. PMID: 23077099 | PMCID: PMC3532474
Waeber B, Siragy HM, Mild hypertension: to treat or not to treat?, 2012; Current hypertension reports. 15(1) 1-2. PMID: 23152161
Matavelli LC, Siragy HM, Reduction of aldosterone production improves renal oxidative stress and fibrosis in diabetic rats., 2012; Journal of cardiovascular pharmacology. 61(1) 17-22. PMID: 23011470 | PMCID: PMC3538933
Huang J, Siragy HM, Sodium depletion enhances renal expression of (pro)renin receptor via cyclic GMP-protein kinase G signaling pathway., 2011; Hypertension. 59(2) 317-23. PMID: 22203739 | PMCID: PMC3266459
Siragy HM, To ACCELERATE hypertension control., 2011; Current hypertension reports. 13(4) 259-61. PMID: 21494776
Matavelli LC, Huang J, Siragy HM, Combined aliskiren and amlodipine reduce albuminuria via reduction in renal inflammation in diabetic rats., 2011; Journal of cardiovascular pharmacology. 59(3) 281-7. PMID: 22075749 | PMCID: PMC3296909
Siragy HM, A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors., 2011; Vascular health and risk management. 7() 297-313. PMID: 21633727 | PMCID: PMC3104607
Abadir PM, Walston JD, Carey RM, Siragy HM, Angiotensin II Type-2 receptors modulate inflammation through signal transducer and activator of transcription proteins 3 phosphorylation and TNFα production., 2011; Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research. 31(6) 471-4. PMID: 21288138 | PMCID: PMC3104285
Huang J, Matavelli LC, Siragy HM, Renal (pro)renin receptor contributes to development of diabetic kidney disease through transforming growth factor-β1-connective tissue growth factor signalling cascade., 2011; Clinical and experimental pharmacology & physiology. 38(4) 215-21. PMID: 21265872 | PMCID: PMC3077929
Siragy HM, Rationale for combining a direct renin inhibitor with other renin- angiotensin system blockers. Focus on aliskiren and combinations., 2011; Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 25(1) 87-97. PMID: 21213120